The emergence of compounds like copyright and Semaglutide signifies a major shift in how we manage type 2 diabetes. These groundbreaking therapies belong to a class known as GLP-1 target agonists, which mimic the effects of a natural hormone that manages sugar levels and food intake. First, devel